[Is more expensive always better?]

If left untreated, hepatitis C infection can lead to hepatitis, liver fibrosis, cirrhosis and hepatocellular carcinoma. Until recently, the standard-of-care was peginterferon with ribavirin. Sofosbuvir is a novel direct antiviral acting agent that targets hepatitis C. Administration of sofosbuvir leads to high cure rates, but is very expensive. Here we question the concept of the value-based pricing of sofosbuvir, and argue that the spiralling price of new drugs leads to an unsustainable healthcare system.